Brian M. Masters

Brian M. Masters

Auto-generated profile, based on publicly available information

Brian M. Masters

Medical Affairs, Veloxis Pharmaceuticals, Inc., Cary, North Carolina

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2019 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
SFSari R. Freedman
Sari R. Freedman
BRBharath R. Ravichandran
Bharath R. Ravichandran
BMBrian M. Masters
Brian M. Masters
JBJonathan S. Bromberg
Jonathan S. Bromberg
AHAbdolreza Haririan
Abdolreza Haririan
TSTracy Sparkes
Tracy Sparkes

3 September 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
BRBharath R. Ravichandran
Bharath R. Ravichandran
TSTracy M. Sparkes
Tracy M. Sparkes
BMBrian M. Masters
Brian M. Masters
BTBeje Thomas
Beje Thomas
MDMoses Demehin
Moses Demehin
AHAbdolreza Haririan
Abdolreza Haririan

24 October 2024 in Therapeutic Drug Monitoring
Verified
Journal Article
Open access
JMJeremiah D. Momper
Jeremiah D. Momper
RVRaman Venkataramanan
Raman Venkataramanan
AJArin S. Jantz
Arin S. Jantz
DCDiane M. Cibrik
Diane M. Cibrik
KBKelly Md Birdwell
Kelly Md Birdwell
SPSamir J. Patel
Samir J. Patel
Background: For extended-release drug formulations, effective half-life (t1/2eff) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t1/2eff of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t1/2eff and terminal half-life (t1/2z) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). Methods: A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T1/2eff was estimated using within-participant accumulation ratios. T1/2z was estimated by linear regression of the terminal phase of the concentration versus time profile. Results: The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively. The median (interquartile range; IQR) t1/2eff for LCPT at day 14 of dosing was 48.4 (37.4–77.9) hours, whereas the t1/2z was 20.3 (17.6–22.9) hours. For IR-Tac, the median (IQR) t1/2eff and t1/2z on day 14 were 12.5 (8.8–23.0) hours and 12.2 (9.2–15.7) hours, respectively. Conclusions: Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t1/2eff compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.

15 July 2014 in Transplantation
Verified
Journal Article
Closed access
BMB. Masters
B. Masters
TST. Sparkes
T. Sparkes
MJM. Jason
M. Jason
SHS. Hanish
S. Hanish
SOS. Ottmann
S. Ottmann
RBR. Barth
R. Barth